[1]
|
Regulation (Ec) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products[J]. OJEC, 2000, 43: 1-5. |
[2]
|
Rare Diseases Act of 2002[Z]. US Congress, 2002. |
[3]
|
Boycott KM, Vanstone MR, Bulman DE, et al. Rare-disease genetics in the era of next-generation sequencing:discovery to translation[J]. Nat Rev Genet, 2013, 14:681-691. https://pubmed.ncbi.nlm.nih.gov/23999272/ |
[4]
|
Therapeutic Goods Regulations 1990[Z]. 1990. |
[5]
|
Japan pharmaceutical manufacturers association information on Japanese regulatory affairs[R].2017. http://www.phar-mexcil.org/v1/docs/Japan_pharmaceutical_Administration.pdf. |
[6]
|
Orphanet. Rare disease registries in Europe[R]. 2017. https://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf. |
[7]
|
Boycott KM, Rath A, Chong JX, et al. International cooperation to enable the diagnosis of all rare genetic diseases[J]. Am J Hum Genet, 2017, 100:695-705. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=902cc323b777606fa160ead32b08ab8f |
[8]
|
U.S. Food & Drug Administration. 2016 Novel drugs summary[R]. 2017. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM536693.pdf. |
[9]
|
Evaluate Pharma. Evaluate Pharma Orphan Drug Report 2017[R]. 2017. http://info.evaluategroup.com/rs/607-YGS-364/images/EPOD17.pdf. |
[10]
|
Wu N, Ming X, Xiao J, et al. TBX6 null variants and a common hypomorphic allele in congenital scoliosis[J]. N Engl J Med, 2015, 372:341-350. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=7e5de689862b44da782b01d6efd1261c |
[11]
|
Sun L, Zhao L, Du L, et al. Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis[J]. Bone Res, 2016, 4:16038. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gyj-e201604005 |
[12]
|
Wu W, Lu CX, Wang YN, et al. Novel phenotype-genotype correlations of restrictive cardiomyopathy with myosin-binding protein c (Mybpc3) gene mutations tested by next-generation sequencing[J]. J Am Heart Assoc, 2015, 4:e001879. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608072/ |
[13]
|
Ding F, Wickman L, Wang SQ, et al. Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome[J]. Kidney Int, 2017.doi: 10.1016/j.kint.2017.0.017.[Epub ahead of print]. |
[14]
|
Hou Y, Yang J, Luo C, et al. Patterns of striatal functional connectivity differ in early and late onset Parkinson's disease[J]. J Neurol, 2016, 263:1993-2003. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=a70d0c422b07dfcb9cde6fcd17648395 |
[15]
|
Wu WH, Yang L, Peng FH, et al. Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2013, 187:303-310. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=78e5ee7a171b3223699d9a0339a56613 |
[16]
|
Xu KF, Lo BH. Lymphangioleiomyomatosis:differential diagnosis and optimal management[J]. Ther Clin Risk Manag, 2014, 10:691-700. doi: 10.2147/TCRM.S50784 |
[17]
|
中共中央办公厅, 国务院办公厅.《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》[Z]. 2017. |
[18]
|
冯时, 弓孟春, 张抒扬.中国国家罕见病注册系统及其队列研究:愿景与实施路线[J].中华内分泌代谢杂志, 2016, 32:977-982. http://d.wanfangdata.com.cn/periodical/zhnfmdx201612001 |
[19]
|
肖磊.患者组织在罕见病和孤儿药研发中的作用[J].国际药学研究杂志, 2017, 2:209-214. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gwyx-yxfc201702022 |
[20]
|
FDA approval brings first gene therapy to the United States[N]. 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm. |
[21]
|
Humphrey M. FDA Consider Approval of US Gene Therapy[N]. 2017. http://www.frontlinegenomics.com/news/13504/fda-consider-approval-of-us-gene-therapy/. |